Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales
Rhea-AI Filing Summary
Entrada Therapeutics Chief Financial Officer Kory James Wentworth reported equity compensation grants and related tax-withholding share dispositions. On March 1, 2026, he received 66,600 stock options and 44,600 restricted stock units under the 2021 Stock Option and Incentive Plan, both vesting in stages through March 1, 2030.
The filing also shows mandatory sell-to-cover transactions where the company automatically sold 5,712 shares at a weighted average price of $11.7564 on March 3, 2026 and 2,939 shares at $11.6579 on March 2, 2026 to cover minimum statutory tax withholding obligations, not discretionary trades by Wentworth. After these transactions, he directly owned 145,975 common shares and 66,600 options.
Positive
- None.
Negative
- None.
Insights
Routine equity grants and automatic tax sales for Entrada’s CFO.
Entrada Therapeutics granted its CFO, Kory James Wentworth, 66,600 stock options and 44,600 RSUs on March 1, 2026. Both awards vest gradually through March 1, 2030, tying a substantial portion of his compensation to long-term company performance.
Two Form 4 entries coded “F” disclose tax-withholding dispositions totaling 8,651 shares of common stock at weighted average prices of $11.7564 and $11.6579. Footnotes clarify these were mandatory sell-to-cover sales executed by the company to satisfy minimum statutory tax obligations, not discretionary market sales.
After these transactions, Wentworth directly held 145,975 common shares and 66,600 options. This pattern reflects standard executive equity compensation and tax handling rather than a directional view on Entrada Therapeutics (TRDA) stock. Subsequent filings may update his vested holdings as tranches vest over time.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 5,712 | $11.7564 | $67K |
| Tax Withholding | Common Stock | 2,939 | $11.6579 | $34K |
| Grant/Award | Stock Option (Right to Buy) | 66,600 | $0.00 | -- |
| Grant/Award | Common Stock | 44,600 | $0.00 | -- |
Footnotes (1)
- Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.
